The relationship between dynapenia and vitamin D level in geriatric women with type 2 diabetes mellitus

Ridvan Sivritepe
Department of Internal Medicine, Istanbul Medipol University Faculty of Medicine Pendik Hospital, Istanbul, Turkey

ABSTRACT

OBJECTIVE: In this study, we examined the possible relationship between dynapenia and vitamin D (VD) levels in geriatric women with type 2 diabetes mellitus (T2DM).

METHODS: One hundred and twenty-two geriatric female patients aged 65–80 years with a diagnosis of T2DM were included in this prospective study. Physical examinations of the patients were performed, and biochemical tests were analyzed. The muscle strength of the patients was measured with a hand dynamometer. Dynapenia was defined as low grip strength with normal skeletal muscle mass index. In muscle strength measurements, for female patients, over 20 kg was accepted as normal and below 20 kg as decreased muscle strength. Patients were separated into three groups as <10 ng/ml, 10–30 ng/ml, and >30 ng/ml according to VD levels; according to the status of dynapenia, they were divided into two groups as dynapenic and non-dynapenic. By comparing all these parameters between these groups, the relationship between VD level and dynapenia was evaluated. In statistical analysis, significance was accepted as p<0.05.

RESULTS: While 54 of the patients (44.3%) met the dynapenia criterion, 68 patients (55.7%) were non-dynapenic. Patients were first compared according to their dynapenia status. VD level was significantly lower in the dynapenic group (p<0.05). In the correlation analysis, a moderate positive correlation was found between muscle strength and VD (p=0.033, r: 0.23). The patients were then compared according to the VD groups. In the VD insufficient group, muscle strength (p=0.015), body mass index (p=0.025), systolic blood pressure (p<0.01), and glucose (p<0.01) were statistically significantly higher.

CONCLUSION: In the present study, we found a considerable relationship between VD levels and dynapenia in geriatric women with T2DM.

Keywords: Dynapenia; geriatrics; type 2 diabetes mellitus; vitamin D.

Cite this article as: Sivritepe R. The relationship between dynapenia and vitamin D level in geriatric women with type 2 diabetes mellitus. North Clin Istanb 2022;9(1):64–73.

Type 2 diabetes mellitus (T2DM) ranks 4th–5th among the causes of death in developing countries and therefore an important public health problem worldwide [1]. Today, more than 400 million people are known to have T2DM, and this number is estimated to reach 642 million by 2040 [1]. Turkey, the Vitamin D deficiency’s (VDD) prevalence is one of the countries with the highest [2]. It is estimated that more than 65% of the country’s population suffers from VDD, and this situation is reported to be higher in the geriatric population [2]. VDD has attracted great caution in recent years, as it improves the quality of life with its treatment and has an important role in health. Many studies have researched the relationship between vitamin D (VD) level and T2DM risk, and it has been determined that VDD itself is a risk factor for the development of T2DM [3–5]. In diabetic patients, VD is not only connected with calcium-phosphorus balance and bone metabolism but
is also one of the hormones involved in the pathophysiology of various chronic illnesses such as metabolic syndrome, obesity, cancer, heart diseases, and dementia [6, 7]. However, recent evidence has shown that VDD may be related with malnutrition and musculoskeletal system diseases [8]. Dynapenia, a consequence of malnutrition, is defined as a decrease in muscle strength due to aging without a reduced muscle mass [9]. As we know that this decrease, which occurs independently of neurological or muscular diseases, impairs physical performance in patients and increases the risk of falls, resulting in mortality and morbidity [9]. Patients with T2DM have been shown to be candidates for dynapenia, and a decrease in muscle mass, strength, and performance has been considered a diabetic complication [10]. There is a study in the literature evaluating the relationship between dynapenia and VD levels, but there are no studies examining these two conditions in diabetic women [11]. Therefore, in the present study, we aimed to evaluate the interrelation between dynapenia and VD levels in women with T2DM.

**MATERIALS AND METHODS**

Our study is a single-center and cross-sectional study. Approval was obtained by the local ethics committee for the study (University of Health Sciences Umraniye Training and Research Hospital Clinical Research Ethics Committee Number: B101TKH434HGP001/69 Date: 11.03.2021), and it was carried out in accordance with the Helsinki Declaration principles. For the present study, all patients were informed about the purpose and procedure and written informed consent was obtained. For the power analysis of the study, reference number 11 was taken as reference [11]. Considering the correlation coefficient between dynapenia and VD being 0.99, the sample size per group was calculated as a minimum of 52, with a Type 1 error of 0.05 and the strength of the study being 80%. With a 20% loss, a total of 125 patients were incorporated in the study. 125 geriatric female patients aged between 65 and 80 years with a diagnosis of T2DM admitted to our internal medicine outpatient clinic were included in the study.

**Inclusion Criteria**
- Between the ages of 65 and 80
- T2DM diagnosis according to American Diabetes Association criteria [12]
- Absence of acute diabetic problems such as diabetic ketoacidosis, hyperosmolar hyperglycaemic coma, or hypoglycemia in the past 3 months
- Having normal kidney and liver functions (Creatinine <1.1 mg/dl, aspartate transferase <34 U/L and alanine aminotransferase <55 U/L)
- A normal lifestyle.

**Exclusion Criteria**
- Under 65 or over 80
- Type 1 DM
- Hypo-hyperthyroidism or hyperparathyroidism
- Use of drugs that may change serum VD levels (such as VD, bisphosphonates, corticosteroid, anticonvulsant, and estrogen) or dietary supplements
- Body mass index (BMI) >30 kg/m²
- Presence of malignancy
- Cushing’s disease
- Addison’s disease
- Presence of sarcopenia
- The presence of quadriplegia, myopathy, or mobility due to stroke
- Severe cardiovascular disease
- Acute or chronic infection
- Diabetic neuropathy
- Major psychiatric illness.

Medical history was taken from all participants and physical examinations were performed. Diabetes duration, daily number of cigarettes smoked, and drug use of all participants was written down. Patients who smoked one pack of cigarettes a day were considered current smokers. Blood pressure was measured with an electronic device (Omron M2 Basic HEM-7121JE Arm Meter Digital Sphygmanometer) in sitting position after a rest period of more than 5 min. Blood pressure and blood samples of the patients were taken between 08:00 and 10:00 h on an empty stomach.
Evaluation of Metabolic Parameters

Biochemical blood tests of all patients were analyzed. Blood samples were taken from the patients, then they were analyzed in the same laboratory. Plasma glucose by the enzymatic test method, glycated hemoglobin by high-performance liquid chromatography method, calcium, phosphate, alanine transaminase, aspartate transaminase, high-density lipoprotein cholesterol, total cholesterol, and triglyceride concentration by enzymatic colorimetric test (Hitachi 747 autoanalyzer, German), creatinine by Jaffe method, blood urea nitrogen by spectrophotometer, potassium, sodium, and chlorine level with ion-selective electrode analysis was measured with Architect plus device. The serum sample taken to measure the VD levels of the patients was centrifuged at 3500 rpm for 15 min and then measured by the electrochemiluminescence method. VD was measured using the Elecsys 2010, Roche Diagnostics, GmbH, Mannheim, Germany device with an intra and inter test coefficient of variation of 3.0% and 3.3%, respectively. The serum VD detection limit was 2 ng/ml. We know that VD level is affected by seasonal factors. Therefore, the study was carried out in January, February, and March. Patients were grouped according to their VD measurement levels as deficient (0–19.9 ng/ml), insufficient (20–29.9 ng/ml), and normal (30 ng/ml) [13].

Definition of Type 2 Diabetes

We used American Diabetes Association criteria to detect the presence of T2DM in patients [12]. The patient was considered to have DM when the fasting blood glucose (8 h fasting) was ≥126 mg/dl and hemoglobin A1c (HbA1C) level 6.5% (48 mmol/mol).

Evaluation of Anthropometric Measurements

The weights of the patients were measured after 12 h of fasting by removing shoes, socks, and heavy clothing, and using an electronic scale (Ekoter mechanical height measuring scales) that are calibrated every day. Their height was evaluated using a standard height gauge (Ekoter mechanical scale with height gauge). Bodyweight (kg)/height squared (m²) formula was used to calculate BMI.

Evaluation of Muscle Strength

The right-left hand muscle strength of the patients was measured with a hydraulic dynamometer (12-0240 Baseline Hydraulic Hand Dynamometer 200 LB Standard W/Case). In the grip strength measurements, the patients were asked to hold the hand dynamometer in a standing upright position with the elbow straight at maximum capacity and squeeze it firmly for 3 s. This procedure was performed three times for each patient and the average of the dominant hand was calculated. Measurements of muscle strength were done before blood sampling so that the test was not affected. In the measurements, more than 20 normal and <20 were accepted as decreased muscle strength for female patients.

Definition of Dynapenia

Patients’ values such as muscle mass (%), body fat ratio (%), metabolism/body fat, and lean body mass volumes were measured using a multi-frequency bioimpedance analysis (BIA) device (Fully automatic body bioimpedance analyzer, Tokyo, Japan). Skeletal muscle mass index (SMMI) was assessed as=|1/BIA resistance result×height²×0.401|+[age×–0.071]+[3.825×gender]|+5.102. In the formula, height: centimeter, resistance: ohm, gender was considered female: 0 and age: year. The cut-off value for SMMI for women was accepted as 6.76 kg/m²: normal, between 5.76 and 6.75 kg/m²: moderate muscle mass reduction, 5.75: severe muscle mass reduction. According to Manini and Clark’s suggestion, dynapenia was defined as although the person has a normal SMMI index, a decrease in muscle grip strength [14].

Statistical Analysis

Results were analyzed using MedCalc Statistical Software version 12.7.7 (MedCalc Software bvba, Ostend, Belgium; http://www.medcalc.org; 2013) was used. Descriptive terms (median, standard deviation, mean, maximum, and minimum) were used to describe continuous parameters in statistical analysis. Comparison of normally distributed continuous variables and independent was made with Student’s t-test. Comparison of two variables that were independent and not compatible with normal distribution was made using the Mann Whitney u test. Pearson correlation coefficient was calculated to determine the relationship between two normally distributed continuous variables, and for interpret relationship between two continuous variables that were not normally distributed Spearman’s rho correlation coefficient was used. Chi-square was used to estimate the relationship between categorical variables. For statistical analysis, Significance level was supposed as p<0.05. By comparing all parameters among the specified groups, the relationship between VD level and dynapenia in diabetic geriatric women was evaluated.
RESULTS

The study was conducted on 122 patients after the three patients who were included in the study left the study voluntarily. The mean age of the patients was 67.7 years, the mean muscle strength was 20 kg, the mean VD was 13.9 ng/ml, the mean HbA1c was 9.3%, and the mean duration of diabetes was 6.8 years. While 54 of the patients (44.3%) met the dynapenia criterion, 68 patients (55.7%) were non-dynapenia. The demographic data, biochemical and clinical parameters, and anthropometric measurements of the patients are shown in Table 1.

VDD was found in 57 (46.7%) of the patients and VD insufficiency in 58 (47.5%), while VD was normal in only 7 (5.8%) patients. While 29.5% of the patients used only oral antidiabetic agents as antidiabetic agents, 38.2% were using only insulin. The percentage of patients using both oral antidiabetic and insulin was 32.3. 39.3% of the patients were non-smokers, 42.6% were active smokers and 18% were ex-smoker.

Patients were first compared as dynapenic and non-dynapenic (Table 2). VD level was found to be statistically significantly lower in the dynapenic group (p<0.05). Although BMI, waist circumference, duration of diabetes, and low-density lipoprotein (LDL) level were found to be lower in the dynapenic group, those were not at a statistically significant level. While diastolic blood pressure, systolic blood pressure, HbA1c, and glucose levels were higher in the dynapenic patient group, this ratio was not statistically significant.

Patients were then compared according to VD levels (Table 3). Since there were not enough patients in the group with normal VD levels, evaluation was made between the group with insufficient and deficient VD. While muscle strength, BMI, SMMI index, and glucose levels were statistically significantly lower (respectively p: 0.015; p: 0.025; p<0.01) in the group with VDD compared to the group with insufficient levels, systolic blood pressure was found to be higher (p<0.01).

| Parameter                        | Mean   | Median | SD   | Minimum | Maximum |
|----------------------------------|--------|--------|------|---------|---------|
| Age (years)                      | 65.7   | 70     | 5.6  | 65      | 80      |
| Muscle strength (kg)             | 20     | 31     | 4.2  | 2       | 44      |
| BMI (kg/m²)                      | 26.9   | 25.05  | 0.7  | 25.6    | 30      |
| Waist circumference (cm)         | 96.7   | 100    | 8.4  | 89      | 128     |
| SMMI index                       | 7.32   | 7.2    | 1.01 | 6.34    | 9.5     |
| Systolic blood pressure (mmHg)   | 124.6  | 130    | 12.5 | 100     | 160     |
| Diastolic blood pressure (mmHg)  | 70.72  | 80     | 8.4  | 65      | 110     |
| Vitamin D (ng/ml)                | 13.9   | 21.55  | 13   | 7.5     | 48.7    |
| HBA1C (%)                        | 9.3    | 8.875  | 4.2  | 5.5     | 14.9    |
| Glucose (mg/dl)                  | 195.5  | 143    | 66.4 | 60      | 563     |
| Sodium (mEq/L)                   | 138.8  | 139.5  | 6.3  | 131     | 147     |
| Creatinine (mg/dl)               | 0.92   | 0.785  | 0.1  | 0.32    | 1.1     |
| Aspartate transaminase (U/L)     | 21.3   | 21.5   | 2.1  | 10      | 34      |
| Diabetes duration (years)        | 6.8    | 7.5    | 6.3  | 1       | 30      |
| HDL (mg/dl)                      | 21.52  | 23     | 3.2  | 18      | 53      |
| LDL (mg/dl)                      | 107.5  | 110    | 5.86 | 68      | 186     |
| Cholesterol (mg/dl)              | 232.26 | 235    | 7.56 | 176     | 302     |
| Potassium (mEq/L)                | 4.48   | 4.25   | 1    | 3.2     | 5.5     |
| Blood urea nitrogen (mg/dL)      | 35.2   | 36.5   | 6.3  | 11      | 72.7    |
| Alanine transaminase (U/L)       | 27.1   | 21     | 2.8  | 6       | 55      |

SD: Standard deviation; BMI: Body mass index; SMMI index: Skeletal muscle mass index; HBA1C: Hemoglobin A1c; HDL: High-density lipoprotein cholesterol; LDL: Low-density lipoprotein cholesterol.

Table 1: Demographic data, anthropometric measurements, clinical and biochemical parameters of the patients (n=122)
In the correlation analysis made between muscle strength and all other parameters; A moderate positive correlation between muscle strength and VD, SMMI index, LDL cholesterol, total cholesterol; A statistical-ly significant negative correlation was found between muscle strength and age, diastolic blood pressure, creatinine. No relationship could be found with other parameters (Table 4).

**DISCUSSION**

In this study, we searched the possible relationship between dynapenia and VD, and we found a clear relationship between VD and dynapenia in this patient group. We found that while VD levels decreased in geriatric women with T2DM, patients’ muscle strength decreased, and VD decreased as muscle strength decreased. To the best of our knowledge, this is valuable because our study is the first study in this field in diabetic geriatric women.

VD has become an important field of study in recent years due to its role in the pathophysiology of many diseases, VD’s receptors (VDR) are discovered in many parts of the body and its positive effects on health by correcting its deficiency [15]. VDD is more common in geriatric individuals with increased fatness, decreased dietary VD intake, cutaneous synthesis of VD, and decreased sun benefit period [16]. Studies in the tropical and subtropical countries such as Turkey, Iran, India, Saudi Arabia, and China have shown that VDD has been seen in more individuals in recent years [2, 17, 18].

It is known that the prevalence of VDD is high in geriatric patients with T2DM, and this deficiency is associated with insulin resistance [4]. The prevalence of VDD was 46.7%, and the prevalence of VD insufficiency was 47.5% in diabetic women in our study. In an 11-year follow-up study, VDD has been shown to increase the risk of T2DM, regardless of family history [19]. In our study, we found that although it was not statistically significant, HbA1c levels were higher in the VD deficient group than

---

**Table 2. Comparison of dynapenic and non-dynapenic patients**

|                      | All patients (n=122) | Dynapenic group (n=54) | Non-dynapenic group (n=68) | p*  |
|----------------------|----------------------|------------------------|-----------------------------|-----|
| Age (years)          | 65.77±9.4            | 50.29±7.53             | 55.24±9.85                  | 0.632|
| Muscle strength (kg) | 20.01±16.5           | 10.92±19.5             | 27.23±12.2                  | 0.01 |
| BMI (kg/m²)          | 26.95±3.22           | 26.84±2.34             | 27.15±2.32                  | 0.513|
| Waist circumference (cm) | 96.63±8.2         | 95.71±7.22             | 96.62±8.39                  | 0.63 |
| SMMI index           | 7.32±1.01            | 7.21±1.03              | 7.34±1.06                   | 0.68 |
| Systolic blood pressure (mmHg) | 138.58±21.5   | 139.05±25.43           | 136.11±23.47                | 0.988|
| Diastolic blood pressure (mmHg) | 74.49±12.53  | 75.95±10.32            | 72.59±11.55                 | 0.351|
| Vitamin D (ng/ml)    | 13.9±9.52            | 14.19±8.73             | 15.71±9.34                  | <0.05|
| HBA1C (%)            | 9.37±3.7             | 9.55±2.99              | 8.98±2.39                   | 0.817|
| Glucose (mg/dl)      | 193.7±95.11          | 186±83.68              | 183.9±88.7                  | 0.551|
| Sodium (mEq/L)       | 138.05±3.2           | 138.76±2.4             | 139.4±2.79                  | 0.538|
| Creatinine (mg/dl)   | 0.99±0.97            | 0.9±0.16               | 0.92±0.25                   | 0.532|
| Aspartate transaminase (U/L) | 23.29±7.33   | 22.57±7.84             | 21.31±9.15                  | 0.576|
| Diabetes duration (years) | 9.52±6.53        | 5.05±3.58              | 7.33±5.79                   | 0.218|
| HDL (mg/dl)          | 38.16±8.78           | 41.62±10.42            | 40±8.65                     | 0.67 |
| LDL (mg/dl)          | 148.32±69.42         | 127.14±33.79           | 137.24±57.39                | 0.591|
| Cholesterol (mg/dl)  | 206.19±53.13         | 210.76±78.96           | 200.42±41.55                | 0.872|
| Potassium (mEq/L)    | 4.49±0.43            | 4.36±0.49              | 4.52±0.41                   | 0.367|
| Blood urea nitrogen (mg/dL) | 36.37±11.7   | 31.87±9.47             | 34.99±9.58                  | 0.162|
| Alanine transaminase (U/L) | 29.95±19.8   | 29.86±14.19            | 28.7±23.59                  | 0.23 |

BMI: Body mass index; SMMI index: Skeletal muscle mass index; HBA1C: Hemoglobin A1c; HDL: High-density lipoprotein cholesterol; LDL: Low-density lipoprotein cholesterol; *: Mann Whitney u test.
| Parameter                        | Vitamin D | n  | Mean | Median | SD     | Minimum | Maximum | p*   |
|---------------------------------|-----------|----|------|--------|--------|---------|---------|------|
| Age (years)                     | <10       | 57 | 68.5 | 67     | 10.01  | 65      | 80      | 0.041|
|                                 | 10–30     | 58 | 65.91| 74     | 7.07   | 69      | 79      |      |
|                                 | >30       | 7  | 68.9 | 68     | 11.2   | 65      | 80      |      |
| Muscle strength (kg)            | <10       | 57 | 15   | 13     | 2.44   | 2       | 44      | 0.015|
|                                 | 10–30     | 58 | 25.52| 24     | 2.83   | 10.1    | 44      |      |
|                                 | >30       | 7  | 25.7 | 28     | 1.65   | 24      | 44      |      |
| BMI (kg/m²)                     | <10       | 57 | 24.25| 27.45  | 2.44   | 24.6    | 32.2    | 0.025|
|                                 | 10–30     | 58 | 26.74| 19.9   | 13.86  | 27.4    | 29.7    |      |
|                                 | >30       | 7  | 25.4 | 25.4   | 1.74   | 25      | 28.4    |      |
| Waist circumference (cm)        | <10       | 57 | 90   | 96     | 9.67   | 89      | 98      | 0.591|
|                                 | 10–30     | 58 | 96.79| 97     | 5.72   | 97      | 128     |      |
|                                 | >30       | 7  | 92.8 | 94     | 4.76   | 85      | 97      |      |
| SMMI index                      | <10       | 57 | 7.00 | 7.1    | 1.01   | 6.3     | 7.3     | <0.05|
|                                 | 10–30     | 58 | 7.13 | 7.2    | 0.98   | 6.4     | 7.9     |      |
|                                 | >30       | 7  | 7.89 | 7.4    | 1.2    | 7.4     | 9.5     |      |
| Systolic blood pressure (mmHg)  | <10       | 57 | 148  | 140    | 18.5   | 110     | 160     | <0.01|
|                                 | 10–30     | 58 | 127  | 130    | 22.7   | 110     | 160     |      |
|                                 | >30       | 7  | 133  | 130    | 28.4   | 100     | 150     |      |
| Diastolic blood pressure (mmHg) | <10       | 57 | 76.74| 80     | 12.83  | 60      | 110     | 0.078|
|                                 | 10–30     | 58 | 70.53| 70     | 9.57   | 65      | 90      |      |
|                                 | >30       | 7  | 73   | 75     | 8.36   | 65      | 85      |      |
| HBA1C (%)                       | <10       | 57 | 9.95 | 9      | 1.88   | 5.5     | 14.9    | 0.132|
|                                 | 10–30     | 58 | 9.81 | 7.7    | 1.09   | 7       | 12.8    |      |
|                                 | >30       | 7  | 8.2  | 7.6    | 1.27   | 6.8     | 11.2    |      |
| Glucose (mg/dl)                 | <10       | 57 | 148  | 194    | 85.11  | 60      | 563     | <0.01|
|                                 | 10–30     | 58 | 188  | 198    | 12.14  | 75      | 365     |      |
|                                 | >30       | 7  | 124  | 152    | 64.68  | 69      | 173     |      |
| Sodium (mEq/L)                  | <10       | 57 | 140  | 139    | 3.02   | 131     | 147     | 0.525|
|                                 | 10–30     | 58 | 139.24| 140     | 3.7    | 140     | 145     |      |
|                                 | >30       | 7  | 140.2| 141    | 3.11   | 137     | 144     |      |
| Creatinine (mg/dl)              | <10       | 57 | 0.905| 0.89   | 0.24   | 0.32    | 1.02    | 0.059|
|                                 | 10–30     | 58 | 0.95 | 0.615  | 0.13   | 0.52    | 1.1     |      |
|                                 | >30       | 7  | 0.7  | 0.76   | 0.22   | 0.32    | 0.93    |      |
| Aspartate transaminase (U/L)    | <10       | 57 | 30   | 19.5   | 7.77   | 10      | 34      | 0.445|
|                                 | 10–30     | 58 | 22.55| 26.5   | 13.44  | 17      | 34      |      |
|                                 | >30       | 7  | 18.4 | 16     | 6.87   | 23      | 28      |      |
| Diabetes duration (years)       | <10       | 57 | 7.5  | 5      | 4.36   | 1       | 30      | 0.285|
|                                 | 10–30     | 58 | 7.98 | 3.5    | 3.54   | 1       | 20      |      |
|                                 | >30       | 7  | 7.2  | 7      | 6.34   | 1       | 15      |      |
| HDL (mg/dl)                     | <10       | 57 | 39.19| 38     | 8.32   | 18      | 53      | 0.524|
|                                 | 10–30     | 58 | 40.26| 40     | 6.52   | 27      | 44      |      |
|                                 | >30       | 7  | 44   | 42     | 10.01  | 29      | 42      |      |
| LDL (mg/dl)                     | <10       | 57 | 133.91| 120.5  | 58.68  | 68      | 186     | 0.165|
|                                 | 10–30     | 58 | 156.27| 134     | 80.84  | 72      | 175     |      |
|                                 | >30       | 7  | 107.6| 117    | 32.05  | 72      | 143     |      |
in the VD deficient group. VDD is known to lower the intracellular calcium level, thereby reducing the level of insulin secretion and beta-cell function, resulting in disruption of the body’s response to glucose [5]. Previous evidence has provided that VDD causes diabetes-related problems such as peripheral neuropathy, nephropathy, retinopathy [20]. Our study showed that this deficiency can also contribute to the development of diabetic myopathy.

Several concepts have been put forward to indicate the severity of malnutrition symptoms and signs. One of them is dynapenia. The word meaning of “Dyna” is “power or strength,” “penia” means “poverty” [9]. Dynapenia means a decrease in muscle strength due to aging, even though the muscle mass is normal and without neurological or muscle diseases [14]. In studies conducted in the Far East, it has been found that the prevalence of dynapenia in women living in rural areas is between 14% and 27% [21–23]. In our study, we found the prevalence of dynapenia to be 44.3%. We think that the explanation for the relatively superior frequency of dynapenia in our study is that the patients included in the study resided in an urban area and were diabetic. Because inactive living in the urban area and diabetes is a big risk factor for dynapenia [14].

The number of studies evaluating the relationship between dynapenia and T2DM has been increasing in recent years. Many studies have shown that T2DM contributes to the reduction of muscle strength [24–26]. Although the mechanisms of the relationship between these

| Parameter                      | Vitamin D | n  | Mean | Median | SD  | Minimum | Maximum | p*        |
|--------------------------------|-----------|----|------|--------|-----|---------|---------|-----------|
| Cholesterol (mg/dl)            | <10       | 57 | 206  | 199    | 61  | 188     | 302     | 0.356     |
|                                | 10–30     | 58 | 206  | 204    | 38  | 182     | 302     |           |
|                                | >30       | 7  | 182  | 183    | 35.1| 176     | 254     |           |
| Potassium (mEq/L)              | <10       | 57 | 4.6  | 4.6    | 0.37| 3.2     | 5.2     | 0.586     |
|                                | 10–30     | 58 | 4.45 | 4.5    | 0.14| 4.4     | 5.5     |           |
|                                | >30       | 7  | 4.32 | 4.4    | 0.54| 3.6     | 5       |           |
| Blood urea nitrogen (mg/dL)    | <10       | 57 | 47.5 | 33.05  | 12.29| 17    | 72.7    | 0.134     |
|                                | 10–30     | 58 | 35.21| 29.05  | 4.31| 26     | 55      |           |
|                                | >30       | 7  | 37.4 | 37.4   | 23.1| 11     | 55      |           |
| Alanine transaminase (U/L)     | <10       | 57 | 22   | 24.5   | 13.43| 6     | 55      | 0.152     |
|                                | 10–30     | 58 | 30.19| 22     | 11.31| 14    | 55      |           |
|                                | >30       | 7  | 16.6 | 16.6   | 6.73 | 8     | 23      |           |

SD: Standard deviation; BMI: Body mass index; SMMI index: Skeletal muscle mass index; HBA1C: Hemoglobin A1c; HDL: High-density lipoprotein cholesterol; LDL: Low-density lipoprotein cholesterol; *: Kruskal Wallis Test.

| Table 3 (cont.). Investigation of parameters according to vitamin D groups |

| Table 4. Correlation analysis between muscle strength and all parameters |

| Muscle strength | Pearson correlation r* | p     |
|-----------------|------------------------|-------|
| Age (years)     | −0.32                  | <0.001|
| BMI (kg/m²)     | −0.048                 | 0.42  |
| Waist circumference (cm) | −0.143          | 0.754 |
| Systolic blood pressure (mmHg) | −0.032     | 0.77  |
| Diastolic blood pressure (mmHg) | −0.066         | <0.001|
| SMMI index      | 0.86                   | <0.001|
| Vitamin D (ng/ml) | 0.23                | 0.005 |
| HBA1C (%)       | 0.085                  | 0.168 |
| Glucose (mg/dl) | −0.051                 | 0.657 |
| Sodium (mEq/L)  | 0.024                  | 0.729 |
| Creatinine (mg/dl) | −0.38                | 0.005 |
| Aspartate transaminase (U/L) | −0.048    | 0.317 |
| Diabetes duration (years) | −0.122        | 0.431 |
| HDL (mg/dl)     | −0.031                 | 0.308 |
| LDL (mg/dl)     | 0.41                   | <0.001|
| Cholesterol (mg/dl) | 0.23              | 0.026 |
| Potassium (mEq/L) | 0.072               | 0.746 |
| Blood urea nitrogen (mg/dL) | −0.085      | 0.98  |
| Alanine transaminase (U/L) | 0.024           | 0.367 |

BMI: Body mass index; SMMI index: Skeletal muscle mass index; HBA1C: Hemoglobin A1c; HDL: High-density lipoprotein cholesterol; LDL: Low-density lipoprotein cholesterol; *: Spearman Rho Coefficient.
two conditions are not fully savvy, it has been recom-
mended that they may be related to insulin resistance and
inflammatory cytokines. Sayer et al. [25] demonstrated
in a study that there was a significant inverse relationship
between muscle grip strength and blood glucose level and
homeostasis model assessment-estimated insulin resis-
tance. It is also claimed that accumulated advanced glyca-
tion products (AGE) in patients with T2DM can lead to
dynapenia by contributing to the reduction of muscle
strength [27]. In addition, the skeletal muscle cell plays
an important role in absorbing and depleting glucose. It
has been shown that myocyte functions are impaired due
to the decrease in Type 4 glucose transporter protein lev-
els in T2DM [28]. In all these studies, it has been shown
that there is a closely relationship between T2DM and
VD and striated muscle functions. However, this pro-
spective study demonstrated for the first time that VD
levels were substantially lower in diabetic geriatric and dy-
apenic women. In the present study, VD level was found
to be statistically significantly lower in dynapenic women.
In addition, diastolic blood pressure, systolic blood pres-
sure, HbA1c, and glucose levels were found to be higher
in the dynapenic patient group. In diabetic women with
VD, we found that hand muscle strength and SMMI
index were statistically significantly lower than the VD
insufficient group. Furthermore, we established a positive
association between VD and muscle strength.

In our study, there was no dissimilarity between dy-
apenic and non-dynapenic groups in terms of hypergly-
cemia therefore, we believe that the reason for the decrease
in muscle strength in these patients is not hyperglycemia
itself, but a direct VDD. At the same time, low muscle
strength causes functional limitations and restricts activ-
ity, causing patients to be deprived of sufficient sunlight
for VD synthesis. As a result, these two situations cause
each other to develop and enter a vicious circle. We can
explain with several mechanisms this significant relation-
ship between low muscle strength and VD in our study.
VDR have been tested in many tissues in the body, par-
ticularly in the beta cells of the pancreas and myocytes.
VD is involved in the expression of more than 200 genes
in these cells [29, 30]. Therefore, VD may directly af-
flect striated muscle metabolism in patients with T2DM
[31]. Having anti-inflammatory properties, VD inhibits
cytokine-induced myocyte cell death in the inflammatory
process. However, it increases the amount of muscle by
increasing the effect of insulin known to be an anabolic
hormone [32]. Therefore, in this case, we can conclude
that sufficient VD level will protect muscle cells and
prevent their progress to dynapenia. In addition to this,
this decreases in muscle strength in patients may have
occurred due to innervation and microenvironmental
defect. Because it is known that VD affects neural stim-
ulation [33]. Therefore, decrease in myocyte functions is
an expected situation in VDD. Furthermore, it has been
shown in studies that VDD causes advanced AGE ac-
cumulation. It has been claimed that these accumulated
AGEs may cause sarcopenia by reducing muscle mass
and strength in patients with T2DM [27]. In our study,
VD caused a decrease in muscle strength while muscle
mass was normal, that is, without developing sarcopenia.
This result makes a new contribution to the current lit-
erature. Recently, it has been discovered that dystrobre-
vin alpha, a member of the dystrophin-related protein
complex, also acts as a VDR gene in skeletal muscle cells
[34]. It is known that active VD synthesis from kidneys
decreases due to aging [7]. Decreased VD cannot be able
to stimulate the protein complex sufficiently. Therefore,
loss of function may occur in myocytes.

In recent studies, it has been observed that the VDR
is expressed to a lesser extent in damaged skeletal muscle
[35, 36]. In a study of mice whose VDR was gradually
destroyed, a decrease in muscle fiber size and muscle
strength was observed [37]. In addition, in these mice, it
was determined that the expression of sarcoplasmic retic-
ulum calcium transporter-ATPase and Calbindin, which
are involved in the regulation of intracellular calcium
concentration, was decreased [37]. It is evident that VD
affects muscle function, improves size and mass, through
related genes. However, the detailed mechanisms on this
issue are still unclear.

It has been observed that the expression of forkhead
box protein O1 (FOXO1), one of the transcription fac-
tors, is increased in some conditions such as malnutri-
tion, inactivity, and cancer [38]. It has been shown that
FOXO1 causes atrophy in myocyte cells through auto-
phagy induction by activating the ubiquitin-proteasome
system [39]. In a different study, it was found that VD
suppresses the transcriptional activity of FOXO1. This
may be one of the possible mechanisms of the link be-
tween dynapenia and VD in our study. However, it has
been claimed that VD can stimulate mechanistic target
of rapamycin complex 1 (mTORC1) signal in mammals
and induce skeletal muscle hypertrophy associated with
it. In a study established by Bass et al. [40] on rats, it
was shown that excessive stimulation of the VDR caused
an increase in mTORC1 and p-p70S6K protein, which
caused hypertrophy in myocyte cells.
Limitations of the Study
Our study had some limitations. First, our study was a cross-sectional study. Therefore, we could not establish a causal relationship between dynapenia and VDD. Second, the patients’ VD levels, anthropometric and muscle strength measurements were evaluated at a single time point. Third, our study was a single-center study, so our results may not be representative of all patients with T2DM. Fourth, there were factors in our study that we could not fix, such as the duration of sunlight exposure, diet, and inactivity. These factors can affect both VD levels and muscle function. Finally, the patients included in the study were middle-aged (65–80 years) women, so it is unclear whether our findings apply to women and men outside this age group. Despite these limitations, our study is important and valuable in raising awareness of dynapenic and VDD in geriatric diabetic women.

Conclusion
We observed a significant relationship between VDD and dynapenia in geriatric women diagnosed with T2DM. We believe that this relationship is caused by VD by increasing regeneration and hypertrophy in myocyte cells, preventing apoptosis, and decreasing AGE accumulation. Our results may guide VD replacement studies for the prevention of dynapenia in women with geriatric T2DM.

Acknowledgements: Thank you for the support of Istanbul Beykoz State Hospital.

Ethics Committee Approval: The University of Health Sciences Umraniye Training and Research Hospital Clinical Research Ethics Committee granted approval for this study (date: 11.03.2021, number: B101TKH434HGP001/69).

Conflict of Interest: No conflict of interest was declared by the author.

Financial Disclosure: The author declared that this study has received no financial support.

REFERENCES
1. Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol 2018;14:88–98.
2. Alpdemir M, Alpdemir MF. Vitamin D deficiency status in Turkey: A meta-analysis. Int J Med Biochem 2019;2:118–31.
3. Lu L, Bennett DA, Millwood EY, Parish S, McCarthy MI, Mahajan A, et al. Association of vitamin D with risk of type 2 diabetes: A Mendelian randomisation study in European and Chinese adults. PLoS Med 2018;15:e1002566.
4. Rafiq S, Jeppesen PB. Body mass index, vitamin D, and type 2 diabetes: a systematic review and meta-analysis. Nutrients 2018;10:1182.
5. Muñoz-Garach A, García-Fontana B, Muñoz-Torres M. Vitamin D status, calcium intake and risk of developing type 2 diabetes: an unresolved issue. Nutrients 2019;11:642.
6. Yin K, Agrawal DK. Vitamin D and inflammatory diseases. J Inflamm Res 2014;7:69–87.
7. Wang H, Chen W, Li D, Yin X, Zhang X, Olsen N, et al. Vitamin D and chronic diseases. Aging Dis 2017;8:346–53.
8. Artaza-Artabe I, Sáez-López P, Sánchez-Hernández N, Fernández-Gutierrez N, Malafarina V. The relationship between nutrition and frailty: Effects of protein intake, nutritional supplementation, vitamin D and exercise on muscle metabolism in the elderly. A systematic review. Maturitas 2016;93:89–99.
9. Clark BC, Manini TM. What is dynapenia? Nutrition 2012;28:495–503.
10. Mori H, Kuroda A, Ishizu M, Ohishi M, Takashi Y, Otsuka Y, et al. Association of accumulated advanced glycation end-products with a high prevalence of sarcopenia and dynapenia in patients with type 2 diabetes. J Diabetes Investig 2019;10:1332–40.
11. Borim FSA, Alexandre TDS, Neri AL, Máximo RO, Silva MF, de Oliveira C. Combined effect of dynapenia (Muscle Weakness) and low vitamin D Status on Incident Disability. J Am Med Dir Assoc 2019;20:47–52.
12. American Diabetes Association. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2020. Diabetes Care 2020;43:S1–31.
13. Pearce SH, Cheetham TD. Diagnosis and management of vitamin D deficiency. BMJ 2010;340:b5664.
14. Manini TM, Clark BC. Dynapenia and aging: an update. J Gerontol A Biol Sci Med Sci 2012;67:28–40.
15. Kula V. Vitamin D metabolism. [Article in Czech]. Vnitr Lek 2012;58:400–4.
16. Gallagher JC. Vitamin D and aging. Endocrinol Metab Clin North Am 2013;42:319–32.
17. Mendes MM, Hart KH, Botelho PB, Lanham-New SA. Vitamin D status in the tropics: Is sunlight exposure the main determinant? Nutr Bull 2018;43:28–34.
18. Joshi K, Bhata V. Vitamin D deficiency in a tropical country-treatment and prevention in children. Indian J Pediatr 2014;81:84–9.
19. Denos M, Mai XM, Åsvold BO, Sørgjerd EP, Chen Y, Sun YQ. Vitamin D status and risk of type 2 diabetes in the Norwegian HUNT cohort study: does family history or genetic predisposition modify the association? BMJ Open Diabetes Res Care 2021;9:e001948.
20. Usluogullari CA, Balkan F, Caner S, Ucer R, Kaya C, Ersoy R, et al. The relationship between microvascular complications and vitamin D deficiency in type 2 diabetes mellitus. BMC Endocr Disord 2015;15:33.
21. Yamada M, Kimura Y, Ishiyama D, Nishio N, Abe Y, Kakuchi T, et al. Differential characteristics of skeletal muscle in community-dwelling older adults. J Am Med Dir Assoc 2017;18:807.
22. Kobayashi K, Imagama S, Ando K, Nakashima H, Machino M, Morozumi M, et al. Dynapenia and physical performance in community-dwelling elderly people in Japan. Nagoya J Med Sci 2020;82:415–24.
23. Koh HM, Park YS. Handgrip strength, dynapenia, and mental health in older Koreans. Sci Rep 2020;10:4004.
24. Nomura T, Ikeda Y, Nakao S, Ito K, Ishida K, Suehiro T, et al. Muscle strength is a marker of insulin resistance in patients with type 2 diabetes: a pilot study. Endocr J 2007;54:791–6.
25. Sayer AA, Dennison EM, Syddall HE, Gilbody HJ, Phillips DI, Cooper C. Type 2 diabetes, muscle strength, and impaired physical function: the tip of the iceberg? Diabetes Care 2005;28:2541–2.
26. Cetinus E, Buyukbese MA, Uzel M, Ekerbicer H, Karaoguz A. Hand grip strength in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 2005;70:278–86.
27. Tabara Y, Ikezoe T, Yamanaka M, Setoh K, Segawa H, Kawaguchi T, et al; Nagahama Study Group. Advanced glycation end product accumulation is associated with low skeletal muscle mass, weak muscle strength, and reduced bone density: the Nagahama Study. J Gerontol A Biol Sci Med Sci 2019;74:1446–53.
28. Daugaard JR, Richter EA. Relationship between muscle fibre composition, glucose transporter protein 4 and exercise training: possible consequences in non-insulin-dependent diabetes mellitus. Acta Physiol Scand 2001;171:267–76.
29. Holick MF. Vitamin D deficiency. N Engl J Med 2007;357:266–81.
30. Ramagopalan SV, Heger A, Berlanga AJ, Maugeri NJ, Lincoln MR, Burrell A, et al. A ChIP-seq defined genome-wide map of vitamin D receptor binding: associations with disease and evolution. Genome Res 2010;20:1352–60.
31. Akagawa M, Miyakoshi N, Kasukawa Y, Ono Y, Yuasa Y, Nagahata I, et al. Effects of activated vitamin D, alfacalcidol, and low-intensity aerobic exercise on osteopenia and muscle atrophy in type 2 diabetes mellitus model rats. PLoS One 2018;13:e0204857.
32. Mathieu C. Vitamin D and diabetes: Where do we stand? Diabetes Res Clin Pract 2015;108:201–9.
33. Nomura T, Ishiguro T, Ohira M, Ikeda Y. Diabetic polyneuropathy is a risk factor for decline of lower extremity strength in patients with type 2 diabetes. J Diabetes Invest 2018;9:186–92.
34. Tsoumpra MK, Sawatsubashi S, Imamura M, Fukumo S, Takeda S, Matsumoto T, et al. Dystrobrevin alpha gene is a direct target of the vitamin D receptor in muscle. J Mol Endocrinol 2020;64:195–208.
35. Srikuea R, Zhang X, Park-Sarge OK, Esser KA. VDR and CYP27B1 are expressed in C2C12 cells and regenerating skeletal muscle: potential role in suppression of myoblast proliferation. Am J Physiol Cell Physiol 2012;303:C396–405.
36. Girgis CM, Mokbel N, Cha KM, Houweling PJ, Abboud M, Fraser DR, et al. The vitamin D receptor (VDR) is expressed in skeletal muscle of male mice and modulates 25-hydroxyvitamin D (25(OH)D) uptake in myofibers. Endocrinology 2014;155:3227–37.
37. Girgis CM, Cha KM, Houweling PJ, Rao R, Mokbel N, Lin M, et al. Vitamin D receptor ablation and vitamin D deficiency result in reduced grip strength, altered muscle fibers, and increased myostatin in mice. Calcif Tissue Int 2015;97:602–10.
38. Lecker SH, Jagoe RT, Gilbert A, Gomes M, Baracos V, Bailey J, et al. Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression. FASEB J 2004;18:39–51.
39. Reed SA, Sandesara PB, Senf SM, Judge AR. Inhibition of FoxO transcriptional activity prevents muscle fiber atrophy during cachexia and induces hypertrophy. FASEB J 2012;26:987–1000.
40. Bass JJ, Nakhuda A, Deane CS, Brook MS, Wilkinson DJ, Phillips BE, etal. Overexpression of the vitamin D receptor (VDR) induces skeletal muscle hypertrophy. Mol Metab 2020;42:101059.